Aro delivers bispecifics, siRNAs where others can’t

A year after its launch, Susan Dillon and Karyn O’Neil’s Aro has begun to reveal details about how the J&J spinout’s Centyrins could form small bispecifics and stable siRNA therapies to penetrate hard-to-reach cancers.

Therapies built from the Centyrin protein scaffold could have more potency than monoclonals to penetrate tumors, and the platform also has the potential to deliver oligonucleotides to tissues outside the liver. ...